ACTU (Actuate Therapeutics) FCF Yield % : -13.98 (As of Mar. 26, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Actuate Therapeutics's Trailing 12-Month Free Cash Flow is $-21.84 Mil, and Market Cap is $156.26 Mil. Therefore, Actuate Therapeutics's FCF Yield % for today is -13.98%.

The historical rank and industry rank for Actuate Therapeutics's FCF Yield % or its related term are showing as below:

ACTU' s FCF Yield % Range Over the Past 10 Years
Min: -49.87 Med: 0 Max: 0
Current: -13.98

ACTU's FCF Yield % is ranked worse than
50.5% of 1501 companies
in the Biotechnology industry
Industry Median: -14.49 vs ACTU: -13.98

Actuate Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

Actuate Therapeutics FCF Yield % Historical Data

The historical data trend for Actuate Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics FCF Yield % Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

FCF Yield %

-14.05

Actuate Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial				-	-	-	-25.15	-12.28

Competitive Comparison of Actuate Therapeutics's FCF Yield %

For the Biotechnology subindustry, Actuate Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's FCF Yield % falls into.

Save Embed

Actuate Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Actuate Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-21.843	/	155.47472
	=	-14.05%

Actuate Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-4.772	*	4	/	155.47472
	=	-12.28%

Actuate Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Actuate Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.